"Global Diabetes Devices and Drugs Market Overview:
Global Diabetes Devices and Drugs Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Diabetes Devices and Drugs Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Diabetes Devices and Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Diabetes Devices and Drugs Market:
The Diabetes Devices and Drugs Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Diabetes Devices and Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Diabetes Devices and Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Diabetes Devices and Drugs market has been segmented into:
Diagnosis and Monitoring (Blood Glucose Monitoring Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Other Testing Devices
By Application, Diabetes Devices and Drugs market has been segmented into:
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Diabetes Devices and Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Diabetes Devices and Drugs market.
Top Key Players Covered in Diabetes Devices and Drugs market are:
Abbott Laboratories
Bristol-Myers Squibb
DexCom
Inc.
Eli Lilly and Company
Companion Medical
GlaxoSmithKline plc
Glenmark Pharmaceuticals
Johnson & Johnson
Lupin Ltd.
F. Hoffmann-La Roche AG
DreaMed Diabetes
Hua Medicine and Sanofi.
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Diabetes Devices and Drugs Market by Type
4.1 Diabetes Devices and Drugs Market Snapshot and Growth Engine
4.2 Diabetes Devices and Drugs Market Overview
4.3 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Diagnosis and Monitoring (Blood Glucose Monitoring Devices: Geographic Segmentation Analysis
4.4 Software Programs for Diabetes Monitoring
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Software Programs for Diabetes Monitoring: Geographic Segmentation Analysis
4.5 Artificial Pancreas
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Artificial Pancreas: Geographic Segmentation Analysis
4.6 Other Testing Devices
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Other Testing Devices: Geographic Segmentation Analysis
Chapter 5: Diabetes Devices and Drugs Market by Application
5.1 Diabetes Devices and Drugs Market Snapshot and Growth Engine
5.2 Diabetes Devices and Drugs Market Overview
5.3 Insulin
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Insulin: Geographic Segmentation Analysis
5.4 Insulin Delivery
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Insulin Delivery: Geographic Segmentation Analysis
5.5 Oral Hypoglycemic Agents
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Oral Hypoglycemic Agents: Geographic Segmentation Analysis
5.6 Cell Therapies
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Cell Therapies: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Diabetes Devices and Drugs Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBOTT LABORATORIES
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BRISTOL-MYERS SQUIBB
6.4 DEXCOM
6.5 INC.
6.6 ELI LILLY AND COMPANY
6.7 COMPANION MEDICAL
6.8 GLAXOSMITHKLINE PLC
6.9 GLENMARK PHARMACEUTICALS
6.10 JOHNSON & JOHNSON
6.11 LUPIN LTD.
6.12 F. HOFFMANN-LA ROCHE AG
6.13 DREAMED DIABETES
6.14 HUA MEDICINE AND SANOFI.
Chapter 7: Global Diabetes Devices and Drugs Market By Region
7.1 Overview
7.2. North America Diabetes Devices and Drugs Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
7.2.4.2 Software Programs for Diabetes Monitoring
7.2.4.3 Artificial Pancreas
7.2.4.4 Other Testing Devices
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Insulin
7.2.5.2 Insulin Delivery
7.2.5.3 Oral Hypoglycemic Agents
7.2.5.4 Cell Therapies
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Diabetes Devices and Drugs Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
7.3.4.2 Software Programs for Diabetes Monitoring
7.3.4.3 Artificial Pancreas
7.3.4.4 Other Testing Devices
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Insulin
7.3.5.2 Insulin Delivery
7.3.5.3 Oral Hypoglycemic Agents
7.3.5.4 Cell Therapies
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Diabetes Devices and Drugs Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
7.4.4.2 Software Programs for Diabetes Monitoring
7.4.4.3 Artificial Pancreas
7.4.4.4 Other Testing Devices
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Insulin
7.4.5.2 Insulin Delivery
7.4.5.3 Oral Hypoglycemic Agents
7.4.5.4 Cell Therapies
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Diabetes Devices and Drugs Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
7.5.4.2 Software Programs for Diabetes Monitoring
7.5.4.3 Artificial Pancreas
7.5.4.4 Other Testing Devices
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Insulin
7.5.5.2 Insulin Delivery
7.5.5.3 Oral Hypoglycemic Agents
7.5.5.4 Cell Therapies
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Diabetes Devices and Drugs Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
7.6.4.2 Software Programs for Diabetes Monitoring
7.6.4.3 Artificial Pancreas
7.6.4.4 Other Testing Devices
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Insulin
7.6.5.2 Insulin Delivery
7.6.5.3 Oral Hypoglycemic Agents
7.6.5.4 Cell Therapies
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Diabetes Devices and Drugs Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Diagnosis and Monitoring (Blood Glucose Monitoring Devices
7.7.4.2 Software Programs for Diabetes Monitoring
7.7.4.3 Artificial Pancreas
7.7.4.4 Other Testing Devices
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Insulin
7.7.5.2 Insulin Delivery
7.7.5.3 Oral Hypoglycemic Agents
7.7.5.4 Cell Therapies
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Diabetes Devices and Drugs Scope:
|
Report Data
|
Diabetes Devices and Drugs Market
|
|
Diabetes Devices and Drugs Market Size in 2025
|
USD XX million
|
|
Diabetes Devices and Drugs CAGR 2025 - 2032
|
XX%
|
|
Diabetes Devices and Drugs Base Year
|
2024
|
|
Diabetes Devices and Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Abbott Laboratories, Bristol-Myers Squibb, DexCom, Inc., Eli Lilly and Company, Companion Medical, GlaxoSmithKline plc, Glenmark Pharmaceuticals, Johnson & Johnson, Lupin Ltd., F. Hoffmann-La Roche AG, DreaMed Diabetes, Hua Medicine and Sanofi..
|
|
Key Segments
|
By Type
Diagnosis and Monitoring (Blood Glucose Monitoring Devices
Software Programs for Diabetes Monitoring
Artificial Pancreas
Other Testing Devices
By Applications
Insulin
Insulin Delivery
Oral Hypoglycemic Agents
Cell Therapies
|
